BlackThorn Therapeutics, Inc.
http://www.blackthornrx.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From BlackThorn Therapeutics, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 8: Therapeutic Area Advances
Neuroscience and oncology fuel high hopes for therapeutic R&D progress among 90-plus surveyed biopharma industry leaders.
Asia Deal Watch: Kelun Partners With Merck A Third Time, Optioning Rights To Seven ADCs
Already partnered on antibody-drug conjugates and a Phase III breast cancer candidate, Merck could pay up to $9.3bn under its third pact in 2022 with Kelun. Eisai divests Fycompa to Catalyst.
Neumora Launches With $500m To Advance Personalized Neuroscience Drugs
Combining biological insights with data science, the start-up emerges from stealth mode after two years of assembling its technology platform and R&D pipeline based on internal and external know-how.
Finance Watch: Polaris Piles On As Multiple Life Science VCs Raise New Funds
Private Company Edition: Polaris is raising up to $400m for its next tech and health care fund, following in the footsteps of several life science investors this year. Also, Nevakar raises $50m in a product financing agreement and RAPT closes a $37m series C extension.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
- Drug Discovery Tools
-
Drug Discovery Tools
- ADMET
- Other Names / Subsidiaries
-
- Neumora Therapeutics, Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice